Blog

  • Samsung HW-Q990F review: Samsung’s Dolby Atmos-in-a-box system returns, with a serious boost to bass

    Samsung HW-Q990F review: Samsung’s Dolby Atmos-in-a-box system returns, with a serious boost to bass

    Why you can trust What Hi-Fi?


    Our expert team reviews products in dedicated test rooms, to help you make the best choice for your budget. Find out more about how we test.

    Home cinema speaker systems are our preferred method of achieving immersive cinematic sound. We’re willing to admit, though, that they are, frankly speaking, a bit of a hassle to set up and live with.

    We wouldn’t blame anyone for not wanting to traipse cables around their living room, or have floorstanding speakers take up precious space – so what’s the alternative?

    Continue Reading

  • Probing The Variations Of Interstellar Dust Abundance And Properties Within And Between Galaxies With HWO UV Spectroscopy In The Local Volume

    Probing The Variations Of Interstellar Dust Abundance And Properties Within And Between Galaxies With HWO UV Spectroscopy In The Local Volume

    (From Lorenzo et al. (2022)) RGB composite image of Sextans A made with Hα (red) and V bands (green) from Massey et al. (2007), and GALEX FUV (blue). The LITTLE THINGS neutral hydrogen map (Hunter et al. 2012) is overlaid in white. OB stars catalogued in Lorenzo et al. (2022) are color-coded according to their spectral type and with different symbols based on their luminosity class. The LUMOS field-of-view is overlaid. In 100h, HWO could obtained FUV and NUV spectra of most of the stars shown in this image with S/N > 20. — astro-ph.GA

    The cycle of metals between the gas and the dust phases in the neutral interstellar medium (ISM) is an integral part of the baryon cycle in galaxies.

    The resulting variations in the abundance and properties of interstellar dust have important implications for how accurately we can trace the chemical enrichment of the universe over cosmic time.

    Multi-object UV spectroscopy with HWO can provide the large samples of abundance and dust depletion measurements needed to understand how the abundance and properties of interstellar dust vary within and between galaxies, thereby observationally addressing important questions about chemical enrichment and galaxy evolution.

    Medium-resolution (R~50,000) spectroscopy in the full UV range (950-3150 A) toward massive stars in Local Volume galaxies (D < 10 Mpc) will enable gas- and dust-phase abundance measurements of key elements, such as Fe, Si, Mg, S, Zn. These measurements will provide an estimate of how the dust abundance varies with environment, in particular metallicity and gas density.

    However, measuring the carbon and oxygen contents of dust requires very high resolution (R > 100,000) and high signal-to-noise (S/N > 100) owing to the non-saturated UV transitions for those elements being extremely weak. Since carbon and oxygen in the neutral ISM contribute the largest metal mass reservoir for dust, it is critical that the HWO design include a grating similar to the HST STIS H gratings providing very high resolution, as well as FUV and NUV detectors capable of reaching very high S/N.

    Julia Roman-Duval, Yumi Choi, Mederic Boquien

    Comments: 12 pages; 6 figures; will be published in ASP conference proceedings of the HWO2025 conference
    Subjects: Astrophysics of Galaxies (astro-ph.GA)
    Cite as: arXiv:2507.00201 [astro-ph.GA] (or arXiv:2507.00201v1 [astro-ph.GA] for this version)
    https://doi.org/10.48550/arXiv.2507.00201
    Focus to learn more
    Submission history
    From: Julia Roman-Duval
    [v1] Mon, 30 Jun 2025 19:10:27 UTC (663 KB)
    https://arxiv.org/abs/2507.00201
    Astrobiology

    Explorers Club Fellow, ex-NASA Space Station Payload manager/space biologist, Away Teams, Journalist, Lapsed climber, Synaesthete, Na’Vi-Jedi-Freman-Buddhist-mix, ASL, Devon Island and Everest Base Camp veteran, (he/him) 🖖🏻

    Continue Reading

  • UK's Palestine Action loses bid to pause ban as 'terror group' – Reuters

    1. UK’s Palestine Action loses bid to pause ban as ‘terror group’  Reuters
    2. Like Palestine Action, the UK called me a ‘terrorist’ once too  Al Jazeera
    3. British group Palestine Action seeks to pause government ban  Dawn
    4. UK lawmakers vote to ban pro-Palestinian activist group under anti-terror law despite condemnation  CNN
    5. ‘Yvette Cooper’ protest group targets ‘Israel-linked’ firms  The New Arab

    Continue Reading

  • The Influence of Lipoprotein(a) on Stent Edge Restenosis and Two-Year

    The Influence of Lipoprotein(a) on Stent Edge Restenosis and Two-Year

    Introduction

    Lipoprotein(a) [Lp(a)] is a unique lipoprotein particle structurally similar to low-density lipoprotein (LDL), consisting of apolipoprotein B-100 covalently linked to apolipoprotein(a) via a disulfide bond.1 Its plasma concentration varies widely among individuals and is primarily determined by genetic factors through an autosomal co-dominant inheritance pattern.2 Lp(a) exhibits both atherogenic and thrombogenic properties due to its structural resemblance to plasminogen and LDL.3 It contributes to lipid deposition, impaired fibrinolysis, inflammation, and smooth muscle cell proliferation,3 thus playing a significant role in the development of atherosclerosis and thrombosis. Elevated Lp(a) levels have been associated with increased cardiovascular risk and recurrent ischemic events in patients with coronary artery disease (CAD) who have undergone percutaneous coronary intervention (PCI).4–6

    Drug-eluting stents (DES), particularly newer-generation devices with thinner struts and more biocompatible polymers, have substantially reduced in-stent restenosis (ISR) and thrombosis rates compared to first-generation stents.7 However, stent edge restenosis (SER)—restenosis occurring at the proximal or distal margins of the stent—remains a relevant limitation.8 SER is often attributed to mechanical and procedural factors, including vascular injury during balloon dilation, residual plaque at the stent edge, mismatches between stent and vessel size, and mechanical stresses at the stent-artery interface.9–11 Additional contributors include hinge motion, plaque burden, and lipid arc presence.11,12 Despite these known mechanical factors, the potential biological contributors to SER, particularly the role of elevated Lp(a), have not been well defined. Given Lp(a)’s proatherogenic and prothrombotic properties, it is biologically plausible that elevated Lp(a) may influence the development of SER. Intravascular ultrasound (IVUS), a high-resolution imaging modality, plays a central role in assessing lesion morphology and plaque characteristics and is therefore instrumental in evaluating the underlying mechanisms of SER. Accordingly, this study aimed to investigate the association between elevated Lp(a) levels and the incidence of SER in patients with CAD undergoing PCI, using IVUS to provide detailed lesion characterization. In particular, the study sought to assess whether elevated Lp(a) levels were associated with specific tissue features of restenosis, such as neoatherosclerosis and neointimal hyperplasia(NIH), to better understand potential biological mechanisms underlying SER.

    Materials and Methods

    Study Population

    This single-center, retrospective observational research initially encompassed 211 consecutive CAD patients receiving IVUS-guided treatment for SER lesions from January 1, 2017 to December 31, 2021. Exclusion criteria encompassed bare metal stent (BMS)-related SER (n=12), absence of serum Lp (a) measurement (n=25), suboptimal IVUS image quality (n=6), serious pulmonary, hepatic, or renal insufficiency (n=8), malignant tumor or autoimmune disease (n=2)(Figure 1). The final cohort was stratified into two cohorts based on serum Lp(a) levels: elevated Lp (a) group (≥50 mg/dL, n=75) and non-elevated Lp (a) group (<50 mg/dL, n=136).13 The study protocol adhered to the Declaration of Helsinki (2013 revision) and received approval from the Research and Ethics Committee of Xiangtan Central Hospital. Written informed consent from all participants or their legal representatives was obtained after they had been fully informed about the objectives of the study (X201863231-3).

    Figure 1 Study flow.

    Abbreviations: SER, stent edge restenosis; PCI, percutaneous coronary intervention; IVUS, intravascular ultrasound; BMS, bare metal stent; Lp(a), lipoprotein(a).

    Clinical Baseline, Procedures and Angiographic Characteristic Data

    A dedicated database captured comprehensive information on patient demographics, comorbidities, and laboratory findings. The choice of interventional strategies, encompassing drug-coated balloon (DCB) angioplasty, second-generation DES implantation, auxiliary device usage, and pharmacotherapy, was determined by operators based on current guidelines and local best practices.14,15 Medication regimens at discharge were documented on dual antiplatelet therapy with 100 mg aspirin daily and a P2Y12 inhibitor (clopidogrel 75 mg daily or ticagrelor 90 mg twice daily), selected according to guideline recommendations and individual bleeding risk assessments. Additional secondary prevention medications, including statins, nitrates, β-blockers, as well as angiotensin-converting enzyme inhibitors, were prescribed in alignment with prevailing guidelines.

    Quantitative coronary angiography (QCA) was conducted using QAngio XA software (Medis Medical Imaging Systems, Leiden, the Netherlands). Coronary lesion morphology evaluation followed previously established methodologies.16 Two experienced angiographers, working independently and blinded to the study details, performed all quantitative measurements using off-line computerized analysis. Lesion images were acquired in at least two orthogonal projections following the administration of 0.5 mg intracoronary nitroglycerin.The major angiographic parameters assessed included minimum lumen diameter (MLD), lesion length, diameter of reference vessel, and percentage diameter stenosis. To minimize procedural variability, all interventions were performed by experienced interventional cardiologists following current PCI guidelines. Decisions on lesion preparation, stent sizing, and landing zone selection were made under IVUS guidance and QCA support. Although lesion preparation techniques (eg, pre-dilation or scoring balloon use) were not uniformly documented, stent deployment adhered to best practices and IVUS-optimized expansion targets.

    Lp(a) Measurement

    Serum Lp(a) levels were quantified using an immune-turbidimetry assay, with ≥50 mg/dL established as a risk-enhancing threshold in accordance with recent guidelines.13 For patients with multiple preprocedural Lp(a) measurements, the value closest to the procedure date was selected for analysis.

    IVUS Image Acquisition and Assessment

    IVUS imaging of SER arteries was performed using a 40-MHz OptiCross™ catheter (Boston Scientific, Marlborough, MA, USA). Following intracoronary nitroglycerin administration (0.1–0.2 mg), automated pullback (0.5 mm/s) was initiated. The IVUS catheter was advanced >10 mm beyond the stent distally and proximally. IVUS image analysis utilized QIvus® software (Medis, Leiden, the Netherlands). SER was defined as >50% diameter stenosis within 5mm proximal or distal to the stent edge.17 Reference segments, representing the most normal-appearing cross-sections in 5 mm of the SER, were identified for comparative analysis (Figure 2). The minimum lumen area (MLA) and minimum stent area (MSA) sites were determined based on smallest lumen/greatest plaque and smallest stent area, respectively. Two independent, blinded cardiologists performed SER identification and quantitative analyses, with high intra-observer as well as inter-observer agreement (κ = 0.92 and 0.90, respectively). NIH area (stent area minus lumen area) and percentage (NIH/stent area) were calculated from stent and lumen areas. Stent expansion was defined as MSA divided via the largest reference lumen,18 with under-expansion classified as MSA <4 mm2 or expansion <50%.19 To further address potential procedural bias, IVUS analysis included parameters related to stent expansion and plaque morphology. The classification of neoatherosclerosis and other SER subtypes was based on consensus definitions and validated by two independent observers. While procedural nuances such as exact lesion preparation were not systematically recorded, the combination of anatomical imaging, blinded review, and high inter-observer agreement (κ = 0.90–0.92) supports the reliability of lesion classification.

    Figure 2 In the example, the coronary angiogram at the time of SER (A) is shown accompanied by a white dotted line indicating the old stents. (BE) in the coronary angiograms correspond to the IVUS image (BE). (B′–E′) are the same images with annotation compared with (BE). IVUS images shown excessive neointimal hyperplasia with good stent expansion; blue dotted lines in the IVUS images indicate old stent struts; the blue asterisks indicate excessive neointimal hyperplasia.

    Abbreviations: SER, stent edge restenosis; IVUS, intravascular ultrasound.

    Definitions

    SER was categorized into five primary patterns: 1) NIH, 2) Neo-atherosclerosis, 3) uncovered lesion, 4) stent under-expansion, and 5) protruding calcified nodule (CN). Neo-atherosclerosis was characterized by atherosclerotic changes at the MLA site within the stent, manifesting as calcified NIH (echogenic tissue with acoustic shadowing), attenuated NIH (ultrasound shadowing without superficial calcium), or ruptured NIH (cavitation within NIH).20 A neo-atherosclerotic calcified nodule was distinguished from a non-neoatherosclerotic protruding calcified nodule, which presented as an irregular, convex calcium deposit within the old stent, lacking adjacent NIH.21 In cases of multiple potential causes, the primary factor contributing to in-stent restenosis was determined based on its predominant impact on stenosis severity.

    Clinical Follow-up and Outcomes

    The study’s primary endpoint focused on device-oriented clinical endpoints (DoCE), encompassing cardiac mortality, myocardial infarction (MI) related to the target vessel or stent thrombosis, and target lesion revascularization (TLR). These clinical outcomes were defined in compliance with the Academic Research Consortium guidelines.22 The investigation prioritized the incidence of DoCE as its main objective, while the secondary goal examined the occurrence of individual DoCE components. Patient monitoring involved periodic assessments at six-month intervals, conducted either through in-person clinical visits or telephone consultations. The follow-up period extended up to two years, with all study participants completing a minimum of one year of observation.

    Statistical Analysis

    Continuous variables were presented as mean ± standard deviation or median (interquartile range), and categorical variables in terms of frequencies and percentages for data presentation. Analysis of continuous outcome data was done by comparing data employing the Student’s t-test or Mann–Whitney U-test, based on the data distribution. Fisher’s exact test was used to evaluate categorical outcome data when the total number of observations was 9 or fewer; chi-square analysis was used if the total number of observations was greater than 9. Cox regression analysis, both univariate and multi-variable, were conducted to ascertain independent determinants of SER, providing odds ratio (OR) with 95% confidence interval (95% CI). Those variables demonstrating P less than 0.10 in univariate analysis were then joined into a multi-variable marginal Cox proportional hazards model. Kaplan-Meier survival assessment was utilized to estimate event rates, and hazard ratios (HR) was calculated from Cox regression analysis. For patients for whom multiple DoCEs were applicable, the first was employed for analytical purposes. All analyses were carried out at a statistical significance of P < 0.05. The statistical program SPSS 24.0 was used to handle and evaluate the data (SPSS Inc., Chicago, IL, US).

    Results

    Baseline Clinical Characteristics and Angiography Characteristics

    The research encompassed 211 patients (136 males, 75 females; mean age 64.28±10.78 years) presenting with SER and 211 corresponding target lesions. Upon analysis, no noteworthy disparities in baseline clinical or angiographic features were detected between subjects with elevated and non-elevated Lp(a) levels (Tables 1 and 2).

    Table 1 Baseline Clinical Characteristics

    Table 2 Angiography Characteristics

    IVUS Analysis of SER Lesions

    The IVUS findings of SER were not different between the elevated Lp(a) cohort and the non-elevated Lp (a) cohort (Table 3). Between the two cohorts, there was a noticeable difference in the distribution pattern of SER stenotic tissue shape. The elevated Lp(a) cohort exhibited fewer instances of NIH compared to the non-elevated Lp(a) cohort (24.0% vs 33.8%, P<0.001)(Figure 3). Conversely, Neo-atherosclerosis was more prevalent in the elevated Lp(a) cohort than in the non-elevated Lp (a) cohort (56.0% vs 44.1%, P<0.001) (Figure 3).

    Table 3 Intravascular Ultrasound Findings

    Figure 3 The primary patterns of SER.

    Abbreviations: CN,calcified nodule; Lp(a), lipoprotein(a); SER, stent edge restenosis.

    Prediction of SER

    As depicted within Table 4, both univariate (OR: 3.612, 95% CI: 2.226–5.477; P<0.001) and multivariate (OR: 3.391, 95% CI: 2.030–5.273; P<0.001) assessments show that elevated Lp(a) was independently correlated with the development of SER.

    Table 4 Univariate and Multivariate Logistic Regression Analysis to Determine the Independent Factors Affecting the Presence of SER

    Clinical Outcomes

    Table 5 and Figure 4 illustrate the comparative clinical outcomes between participants with elevated and non-elevated Lp(a) levels. Over a 2-year observational follow-up period, the elevated Lp(a) cohort consistently demonstrated higher incidences of DoCE and TLR compared to the non-elevated Lp(a) cohort (16.0% vs 7.4%, P<0.001; 13.3% vs 5.1%, P= 0.011, respectively).

    Table 5 Clinical Outcomes During Follow-up

    Figure 4 Kaplan-Meier survival curves of DoCE for 2 years.

    Abbreviations: DoCE, device-oriented clinical endpoints; MI, myocardial infarction; TLR, target lesion revascularization; 95% CI, 95% confidence intervals; HR, hazard ratio; Lp(a), lipoprotein(a).

    Discussion

    This study’s principal observations can be summarized as follows: 1.Among patients with SER, Neo-atherosclerosis was much more prevalent within the elevated Lp(a) cohort. 2.NIH was less frequent in the elevated Lp(a) cohort. 3.Elevated Lp(a) levels exhibited an independent correlation with SER. 4.The cumulative 2-year incidence of both DoCE and TLR was consistently elevated within the elevated Lp(a) cohort.

    Impact of Lp(a) on SER

    This real-world investigation reveals a notable disparity in the distribution of SER stenotic tissue structure between the two cohorts. The elevated Lp(a) cohort exhibited fewer instances of NIH but a higher prevalence of neo-atherosclerosis compared to their counterparts with non-elevated Lp(a) levels. Lp(a) promotes atherosclerosis by transporting cholesterol while adhering to macrophages, facilitating foam cell formation, which contributes to atherosclerotic plaque development.23 In addition, Lp(a) competes for specific binding sites with plasminogen and enhances the activity of plasminogen activator inhibitor, both processes promoting thrombogenesis.24 The post-stent implantation inflammatory response is badly affected by Lp(a). Through its actions on white blood cells and the immune cascades at sites of injured vessel walls, it stimulates proinflammatory cytokine and matrix metalloproteinase secretion. It triggers a localized inflammatory response and then promotes vascular smooth muscle proliferation and migration towards atherosclerotic lesions.25 A second potential proatherogenic mechanism of Lp(a) is its inverse association with vascular reactivity. Lp(a) directly binds to the extracellular matrix, is internalized via macrophages, and is associated with lipid accumulation and Neo-atherosclerosis and in-stent restenosis.26 As a consequence, increased plasma Lp(a) levels result in endothelial dysfunction,27 a major impetus for SER development.28

    Predictors of SER

    The development, severity, as well as pattern of SER are due to multiple factors, such as mechanical (stent under-expansion, uneven drug distribution, and stent fracture), biological (drug resistance and hypersensitivity), or operator-related technical factors (barotraumas beyond the stented section, stent gaps, and remaining uncovered atherosclerotic plaques).29 Our study corroborates that elevated Lp(a) levels independently correlate with an elevated SER risk, supporting Lp(a)’s potential impact on restenotic lesions. However, previous IVUS and optical coherence tomography (OCT) studies have highlighted several key risk factors for SER: mechanical injury, hinge motion, stent under-expansion, smaller lumen size, residual plaque at the stent edge PCI, and a larger step-up index (ie, the ratio of stent border to reference minimum lumen area).11,30,31 A retrospective OCT study of 319 patients immediately after everolimus-eluting stent implantation revealed lipidic plaque (OR: 5.99; 95% CI: 2.89–12.81; P<0.001) and minimum lumen area (OR: 0.64; 95% CI: 0.42–0.96; P=0.029) as independent predictors of SER.11 For post-PCI patients, intensive management directed toward conventional risk factors (elevated LDL level, lesion morphology, hypertension, and diabetes) is usually performed.32 Our cohort’s lack of correlation between these conventional risk variables and SER could be due to the fact that their potential influence may not be a major driver of SER and that the control of these risk factors through intense treatment interventions following baseline PCI has been effective. In contrast, secondary prevention with Lp(a)-targeted therapies is approved but only in development and not yet standardized, giving us the advantage to study the persistent effect of elevated Lp(a) levels on stent durability.

    Clinical Outcome

    Our study revealed consistently higher cumulative 2-year incidences of DoCE and TLR in the elevated Lp(a) cohort in contrast to the non-elevated Lp(a) cohort. The association seen in SER patients with elevated Lp(a) and adverse clinical outcomes following repeat PCI indicated these findings as a potential causal effect even in the DES era. Landmark assessment showed that the differences in SER in patients with elevated and non-elevated Lp(a) were greatest following the index post-baseline PCI and therefore consistent with Lp(a)’s 2-year clinical effects on SER. In fact, a previous OCT study has shown that 185° of lipid arc and a minimal lumen area of 4.10 mm² at the stent edge predict SER and future adverse clinical events.11

    Limited data exist on the association involving Lp(a) levels and stent thrombosis risk following PCI with DES. Due to structural homology between apolipoprotein(a) and plasminogen, Lp(a) may compete with and inhibit tissue plasminogen’s thrombolytic activity.33 Park et al reported an association involving higher Lp(a) levels as well as stent thrombosis following PCI with DES,34 suggesting a more thrombogenic state within patients having high Lp(a) levels. However, our study found no statistically significant difference in cumulative 2-year stent thrombosis incidence involving the two cohorts, possibly due to insufficient sample size. Larger sample size studies are needed to draw definitive conclusions about Lp(a)’s role in stent thrombosis development.

    Despite high and similar statin use in both cohorts (85.3% in elevated Lp(a) cohort versus 89.7% in non-elevated Lp(a) group, P=0.601), significant differences in 2-year DoCE outcomes were observed, suggesting that Lp(a) is not modified by statin therapy.35 Following treatment with a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i), which decreased Lp(a) levels from 71.5 to 47.4 mg/dL, a patient with elevated Lp(a) levels showed no ISR recurrence, according to a case report by Akiyama et al. It is noteworthy that before to starting PCSK9i, this patient had a history of recurrent ISR (6 times) while receiving appropriate traditional antihyperlipidemia medication. Further studies are warranted to investigate potential therapies for preventing SER within patients having high Lp(a) levels undergoing PCI with DES.

    Lp(a) is discussed as a promising risk factor and therapeutic target for SER prevention, and research in this area is encouraged. In patients undergoing PCI, elevated Lp(a) levels should be managed meticulously with a corresponding decrease in Lp(a) level. Of particular relevance in this era of emerging Lp(a)-targeted therapies,36 this approach is important.The clinical importance of Lp(a) in the prevention of SER is amplified because SER is routinely treated by revascularization, which may be complex PCI or surgical intervention and could affect patient prognosis.29 In addition, though, beyond treatment trials, more prospective studies are necessary to better explore the role of Lp(a) in SER.

    Limitations

    This study has several limitations. First, the single-center, non-randomized, retrospective design and limited sample size may introduce selection and information bias. Additionally, some patients were excluded due to missing IVUS assessments or Lp(a) measurements, which may have affected representativeness. Second, the types of DES previously implanted at SER sites included both first- and second-generation devices, potentially influencing plaque morphology and confounding the analysis. Third, although patients received guideline-directed medical therapy, detailed information on prior pharmacological interventions—particularly statin and P2Y12 inhibitor use—was not fully available, which may have contributed to observed differences in restenotic tissue characteristics between cohorts. Fourth, while clinical follow-up was performed for up to two years, extended long-term data beyond this period, including major adverse cardiovascular events (MACE) or late revascularization rates, were not collected. This may have limited the ability to fully assess the long-term prognostic implications of elevated Lp(a). In addition, dynamic changes in Lp(a) levels and longitudinal data on stent type during follow-up were not available, which may have further influenced outcomes. Fifth, while IVUS provided detailed structural information, it has intrinsic limitations in accurately characterizing tissue composition, as its imaging features may not fully correspond with histopathological findings. Future studies incorporating multimodal imaging—such as OCT, NIRS, or hybrid imaging platforms—are warranted to improve tissue characterization and validation.

    Conclusion

    This study demonstrates that elevated Lp(a) is independently associated with the occurrence of neoatherosclerosis and adverse two-year outcomes in patients with SER after PCI. These findings reinforce the biological plausibility of Lp(a) as a risk factor, given its pro-inflammatory and pro-thrombotic properties that may promote plaque progression and vascular remodeling. The results highlight the potential of Lp(a) not only as a predictor of SER but also as a future therapeutic target or risk stratification tool in post-PCI patient management. While the findings are supported by robust imaging and clinical analysis, the single-center, retrospective design and limited follow-up duration represent inherent limitations. Future prospective, multicenter studies with extended follow-up are warranted to validate these observations and assess the impact of Lp(a)-targeted interventions.

    Data Sharing Statement

    The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

    Ethics Approval and Consent to Participate

    The present research was carried out in accordance with the tenets mentioned in the Helsinki Declaration and was approved by the Ethical Board of Xiangtan Central Hospital (approval number:X201863231-3). Prior to the commencement of the research, our team obtained written informed consent from each patient.

    Consent for Publication

    Not applicable. No individual patient data will be reported.

    Author Contributions

    All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas. Specifically, X.W. and L.W. conceived the study and critically reviewed the manuscript for important intellectual content. H.B.H. and H.H. performed the literature search and data analysis. X.W., M.X.W., L.W., Z.L., and H.H. contributed to drafting and revising the manuscript. All authors gave final approval of the version to be published, agreed on the journal to which the article has been submitted, and agree to be accountable for all aspects of the work.

    Funding

    This work was supported by Natural Science Foundation of Hunan Province (No.2022JJ30575) and Health Research Project of Hunan Provincial Health Commission (No. 20233486).

    Disclosure

    The authors declare that they have no competing interests.

    References

    1. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism. 2013;62(4):479–491. doi:10.1016/j.metabol.2012.07.024

    2. Akita H, Matsubara M, Shibuya H, Fuda H, Chiba H. Effect of ageing on plasma lipoprotein(a) levels. Ann Clin Biochem. 2002;39(Pt 3):237–240. doi:10.1258/0004563021901937

    3. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260(5114):1655–1658. doi:10.1126/science.8503012

    4. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease large-scale prospective data. Arch Int Med. 2008;168(6):598–608. doi:10.1001/archinte.168.6.598

    5. Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017;5(7):524–533. doi:10.1016/s2213-8587(17)30088-8

    6. Yoon YH, Ahn JM, Kang DY, et al. Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention. JACC Cardiovasc Interv. 2021;14(18):2059–2068. doi:10.1016/j.jcin.2021.07.042

    7. Kitahara H, Kobayashi Y, Takebayashi H, et al. Angiographic patterns of restenosis after sirolimus-eluting stent implantation. Circ J. 2009;73(3):508–511. doi:10.1253/circj.cj-08-0720

    8. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–1907. doi:10.1016/j.jacc.2010.07.028

    9. Kim YG, Oh IY, Kwon YW, et al. Mechanism of edge restenosis after drug-eluting stent implantation. Angulation at the edge and mechanical properties of the stent. Circ J. 2013;77(12):2928–2935. doi:10.1253/circj.cj-12-1259

    10. Kitahara H, Okada K, Kimura T, et al. Impact of stent size selection on acute and long-term outcomes after drug-eluting stent implantation in de novo coronary lesions. Circulation. 2017;10(10). doi:10.1161/circinterventions.116.004795

    11. Ino Y, Kubo T, Matsuo Y, et al. Optical coherence tomography predictors for edge restenosis after everolimus-eluting stent implantation. Circulation. 2016;9(10). doi:10.1161/circinterventions.116.004231

    12. Jimba T, Ikutomi M, Tsukamoto A, Matsushita M, Yamasaki M. Effect of hinge motion on stent edge-related restenosis after right coronary artery treatment in the current drug-eluting stent era. Circ J. 2021;85(11):1959–1968. doi:10.1253/circj.CJ-21-0196

    13. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;73(24):3168–3209. doi:10.1016/j.jacc.2018.11.002

    14. Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. 2020;13(12):1391–1402. doi:10.1016/j.jcin.2020.02.043

    15. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 1988;78(2):486–502. doi:10.1161/01.cir.78.2.486

    16. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. implications for patient selection. multivessel angioplasty prognosis study group. Circulation. 1990;82(4):1193–1202. doi:10.1161/01.cir.82.4.1193

    17. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872–1878. doi:10.1161/01.cir.100.18.1872

    18. Nasu K, Oikawa Y, Habara M, et al. Efficacy of biolimus A9-eluting stent for treatment of right coronary ostial lesion with intravascular ultrasound guidance: a multi-center registry. Cardiovasc Interv Ther. 2018;33(4):321–327. doi:10.1007/s12928-017-0487-4

    19. Song L, Mintz GS, Yin D, et al. Characteristics of early versus late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study. EuroIntervention. 2017;13(3):294–302. doi:10.4244/eij-d-16-00787

    20. Lee CW, Kang SJ, Park DW, et al. Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. J Am Coll Cardiol. 2010;55(18):1936–1942. doi:10.1016/j.jacc.2009.10.077

    21. Nakamura N, Torii S, Tsuchiya H, et al. Formation of calcified nodule as a cause of early in-stent restenosis in patients undergoing dialysis. J Am Heart Assoc. 2020;9(19):e016595. doi:10.1161/jaha.120.016595

    22. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–2351. doi:10.1161/circulationaha.106.685313

    23. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. New Engl J Med. 2005;353(1):46–57. doi:10.1056/NEJMoa043175

    24. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853. doi:10.1093/eurheartj/ehq386

    25. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nature Genet. 2013;45(1):25–33. doi:10.1038/ng.2480

    26. Fang Y, Lin M, Chen L, Yang C, Liu A. Association between LDL/HDL ratio and in-stent restenosis in patients with acute coronary syndrome after stent implantation. Biomarkers Med. 2022;16(9):673–680. doi:10.2217/bmm-2021-1089

    27. Wu HD, Berglund L, Dimayuga C, et al. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol. 2004;43(10):1828–1833. doi:10.1016/j.jacc.2003.08.066

    28. Patti G, Pasceri V, Melfi R, et al. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation. 2005;111(1):70–75. doi:10.1161/01.Cir.0000151308.06673.D2

    29. Otake H. Stent edge restenosis- an inevitable drawback of stenting? Circulation J. 2021;85(11):1969–1971. doi:10.1253/circj.CJ-21-0581

    30. Wang Y, Lou X, Xu X, Zhu J, Shang Y. Drug-eluting balloons versus drug-eluting stents for the management of in-stent restenosis: a meta-analysis of randomized and observational studies. J Cardiol. 2017;70(5):446–453. doi:10.1016/j.jjcc.2016.12.019

    31. Kang SJ, Cho YR, Park GM, et al. Intravascular ultrasound predictors for edge restenosis after newer generation drug-eluting stent implantation. Am J Cardiol. 2013;111(10):1408–1414. doi:10.1016/j.amjcard.2013.01.288

    32. Shafiabadi Hassani N, Ogliari LC, de Oliveira Salerno PR V, Pereira GTR, Ribeiro MH, Palma Dallan LA. In-Stent restenosis overview: from intravascular imaging to optimal percutaneous coronary intervention management. Medicina. 2024;60(4). doi:10.3390/medicina60040549

    33. Feric NT, Boffa MB, Johnston SM, Koschinsky ML. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. J Thromb Haemost. 2008;6(12):2113–2120. doi:10.1111/j.1538-7836.2008.03183.x

    34. Park SH, Rha SW, Choi BG, et al. Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population. Clin Exp Pharmacol Physiol. 2015;42(6):588–595. doi:10.1111/1440-1681.12396

    35. Nicholls SJ, Tang WH, Scoffone H, et al. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res. 2010;51(10):3055–3061. doi:10.1194/jlr.M008961

    36. Farina JM, Pereyra M, Mahmoud AK, et al. Current management and future perspectives in the treatment of lp(a) with a focus on the prevention of cardiovascular diseases. Pharmaceuticals. 2023;16(7). doi:10.3390/ph16070919

    Continue Reading

  • Ban on Palestine Action to take effect after legal challenge fails | Counter-terrorism policy

    Ban on Palestine Action to take effect after legal challenge fails | Counter-terrorism policy

    Being a member of, or showing support for, Palestine Action will be a criminal offence from Saturday after a last-minute legal challenge to suspend the group’s proscription under anti-terrorism laws failed.

    Huda Ammori of Palestine Action. Photograph: Abdullah Bailey

    A ban on Palestine Action, which uses direct action to mainly target Israeli weapons factories in the UK and their supply chain, was voted through by parliament this week but lawyers acting for its co-founder Huda Ammori had sought to prevent it taking effect.

    After a hearing at the high court on Friday, however, Mr Justice Chamberlain declined to grant her application for interim relief.

    It means Palestine Action will become the first direct action protest group to be banned under the Terrorism Act, placing it in the same category as Islamic State, al-Qaida and the far-right group National Action.

    UN experts, civil liberties groups, cultural figures and hundreds of lawyers have condemned the ban as draconian and said it sets a dangerous precedent by conflating protest with terrorism.

    Another hearing is scheduled for 21 July when Palestine Action will apply for permission for a judicial review to quash the order. In the meantime, and unless the judicial review is successful, membership of, or inviting support for, the group will carry a maximum sentence of 14 years in prison.

    Continue Reading

  • UEFA Women’s EURO 2025 – Clara Mateo exclusive: “I learned a lot from the disappointment”

    UEFA Women’s EURO 2025 – Clara Mateo exclusive: “I learned a lot from the disappointment”

    On a brisk autumnal day in late October, the French women’s national football team kicked off the new Olympic cycle against Jamaica.

    The result was a resounding success.

    A 3-0 convincing win over the Reggae Girlz showed a fierce intent, and for the newly appointed Laurent Bonadei, it was the perfect start.

    Clara Mateo, selected in the number 10 shirt for Bonadei’s first XI, notably looked at ease in the role, running the front line with authority.

    When the opportunity came, she opened the scoring with a low drive in the 22nd minute, clenching her fist in conquest before turning to celebrate with teammate Delphine Cascarino.

    It was a moment of great pride for the striker. Just a few weeks after not being selected for the Olympic Games Paris 2024, she found herself cheered by a standing ovation. The goal proved to be an apt reward, not only for the occasion, but also for the hungry Mateo, who didn’t stop working on her international dream even after the disappointment.

    “It’s true that I had a very good start to the season,” she told Olympics.com in an exclusive interview.

    “I was very happy to be back with the French team. When you’re a top-level athlete, you always want to represent your country. To be able to play and score right from the start of the match, I was obviously very happy. And it also showed the work I’d done to bounce back.”

    As the rest of the season unfurled, the 27-year-old was similarly productive.

    She finished as the top scorer in the French league with 18 goals to her name and was voted the best player by her peers.

    “It’s been a successful season. It’s also a season that rewards the work I’ve put in over the last few years,” she continued. “On an individual level, I was there in terms of statistics, and I was consistent and efficient throughout the season. And then to win a trophy with my club was a real source of pride and emotion.”

    But how did she rebuild into the form of her life after missing out on the Games?

    Olympics.com caught up with the Nantes native at Clairefontaine, just a few days before Les Bleues take on defending champions England at UEFA Women’s EURO 2025, to find out.

    Continue Reading

  • Katy Perry, Orlando Bloom Split Confirmed by Reps

    Katy Perry, Orlando Bloom Split Confirmed by Reps

    One week after multiple outlets reported that Katy Perry and Orlando Bloom had ended their relationship after nine years together, reps for the pair confirmed the split in a statement.

    “Due to the abundance of recent interest and conversation surrounding Orlando Bloom and Katy Perry’s relationship, representatives have confirmed that Orlando and Katy have been shifting their relationship over the past many months to focus on co-parenting,” they said in a statement to Billboard. “They will continue to be seen together as a family, as their shared priority is — and always will be — raising their daughter [Daisy Dove] with love, stability and mutual respect.”

    After weeks of rumors about trouble in their romance, People, TMZ and Us Weekly all independently confirmed in late June that the pair had ended their engagement and gone their separate ways. The two first began dating in 2016 and split briefly in early 2017, but were spotted getting cozy just months later. The Grammy nominee then teased in an Instagram post in February 2018 that she and the Pirates of the Caribbean star had gotten engaged on Valentine’s Day, with the photo focused on a flower-shaped ruby and diamond ring on her finger and the actor snuggling into her. She confirmed the engagement later that month during an appearance on Jimmy Kimmel Live!, revealing that Bloom had proposed to her during a romantic helicopter ride.

    The two welcomed daughter Daisy Dove in August 2020, with the happy news revealed via an announcement from Unicef, for who Bloom and Perry were Goodwill Ambassadors. The pair never married.

    Continue Reading

  • STAGE SET FOR FINALS SHOWDOWN IN MARSTRAND – – World Match Racing Tour

    1. STAGE SET FOR FINALS SHOWDOWN IN MARSTRAND  – World Match Racing Tour
    2. Women’s International Match Racing Association News Detail  wimra.org
    3. Crucial points in tactical day at GKSS Match Cup Sweden  Pressmare
    4. World Match Racing Tour: Sweden Semi-Finalists Revealed  Nautica.News
    5. WMRT. Picture perfect opening day at Marstrand  Pressmare

    Continue Reading

  • McLaren’s Lando Norris leads Ferrari duo Charles Leclerc and Lewis Hamilton in second practice

    McLaren’s Lando Norris leads Ferrari duo Charles Leclerc and Lewis Hamilton in second practice

    Lando Norris finished fastest in Free Practice 2 for the British Grand Prix, the McLaren driver besting the Ferraris of Charles Leclerc and Lewis Hamilton.

    The Briton, who won last time out in Austria, posted a 1m 25.816s that left him 0.222s clear of Leclerc, and three-tenths faster than Hamilton, who had topped FP1 earlier in the day.

    With wind speed high and impacting aerodynamic performance through the high speed turns at Silverstone, teams battled to find the optimum set-up in the changeable conditions.

    Hamilton immediately continued his impressive Friday form, moving to the top of the times with his first flying lap on Pirelli’s medium tyre with a 1m 27.280s, as traffic became an issue for Norris and Liam Lawson.

    Drivers’ Championship leader Oscar Piastri, who earlier had a radio message about the “gusty” conditions, moved to the top of the leaderboard after the opening 10 minutes, only to be immediately usurped by Hamilton and Isack Hadjar.

    While Ollie Bearman complained of oversteer in his Haas, reigning World Champion Max Verstappen was also left frustrated, proclaiming over the radio: “Have you seen my front tyres in the high speed? They just don’t respond.”

    Carlos Sainz soon suffered a harmless spin coming out of Luffield, with Williams Team Principal James Vowles stating “the gusts are definitely catching us out” during the session.

    The second Ferrari of Leclerc took over from his team mate at the top of the times briefly but Hamilton, who has a record nine F1 wins at Silverstone, stamped his authority to go 0.295s clear on a 1m 26.592s after 20 minutes.

    George Russell became the first driver to use a set of Pirelli’s soft tyre, the red-walled compound launching him up to first before Mercedes team mate Kimi Antonelli went 0.140s faster.

    It left the benchmark at a 1m 26.383s, half a second faster than Hamilton’s best from FP1, approaching the halfway point of the one-hour session.

    Times began to tumble as drivers performed Qualifying simulations, with Leclerc and then Norris going fastest, the former complaining of something wrong with the front-left tyre, stating there was “so much lap time in it”.

    Hamilton abandoned his first flying lap on the softs, before moving up to P2 with his second effort, while Verstappen could only manage eighth, eight tenths in arrears on Norris’ 1m 25.816s, improving to fifth on his next run.

    The McLaren driver’s time stood as the benchmark for the remainder of the session, making him the only driver to dip below the 1m 26s barrier as focus switched to long runs for teams.

    As Leclerc and Hamilton completed the top three, Piastri sat in fourth, almost half a second behind his team mate but ahead of Verstappen and Antonelli.

    The Aston Martin of Lance Stroll, Mercedes of Russell and the Racing Bulls of Isack Hadjar and Lawson completed the top 10.

    Alex Albon (P11) was the highest-placed of the Williams drivers, from Aston Martin’s Fernando Alonso and Gabriel Bortoleto, the Brazilian back in his Kick Sauber after the seat was taken by Paul Aron in FP1.

    Esteban Ocon finished 14th, ahead of Yuki Tsunoda, who had also missed FP1 with Arvid Lindblad taking his seat, with Sainz 16th and under investigation following his rejoin after his earlier spin.

    Nico Hulkenberg, who had to avoid Sainz’s recovery, finished P17, as the Alpine’s of Pierre Gasly and Franco Colapinto finished either side of Bearman in P19.

    Continue Reading

  • Hydrothermal Systems May Have Supplied Essential Phosphorus For Early Life

    Hydrothermal Systems May Have Supplied Essential Phosphorus For Early Life

    Hydrothermal Systems May Have Supplied Essential Phosphorus For Early Life — Tohoku University

    Understanding where and in what quantities essential elements for life have existed on Earth’s surface helps explain the origin and evolution of life. Phosphorus (P) is one such element, forming the backbone of DNA, RNA, and cellular membranes. On Earth’s surface, P is primarily preserved in rocks in the form of phosphate minerals. However, these phosphate minerals are generally insoluble. Therefore, scientists have long struggled to answer the question of under what conditions P could have become concentrated on the early Earth.

    Now, a research team comprising Yuya Tsukamoto and Takeshi Kakegawa from Tohoku University may have found the answer. For the first time, they have uncovered geochemical and mineralogical evidence that submarine hydrothermal alteration may have been a significant source of P on the early Earth.

    “We analyzed 3.455-billion-year-old basaltic seafloor rocks in drill core samples recovered from the Pilbara Craton, Western Australia, discovering that P was significantly leached from the hydrothermally altered rocks compared to the least altered rocks” with further mineralogical analyses indicating that phosphate minerals had undergone dissolution in rocks where P was depleted explains,” explains Tsukamoto. “In other words, these hydrothermal processes may have released phosphorus from the rocks into the surrounding seawater, enriching early oceans with this essential nutrient.”

    Schematic image of this study. ©Tsukamoto and Kakegawa et al. — Tohoku University

    The team identified that this significant dissolution was caused by two types of hydrothermal fluids: sulfidic and high-temperature fluids, and mildly acidic to alkaline and relatively low-temperature fluids. In particular, the latter fluids are characteristic of the Archean, reflecting a high CO₂ atmosphere at that time.

    Calculations indicated that these latter fluids could contain up to 2 mM phosphate, approximately 1,000 times higher than modern seawater concentrations. Furthermore, calculations based on the study’s analytical results suggested that the annual flux of P from Archean submarine hydrothermal fluids could have been comparable to that supplied to the modern ocean by continental weathering.

    “Importantly, this study provides direct evidence that submarine hydrothermal activity leached P from seafloor basaltic rocks and quantifies the potential P flux from these hydrothermal systems to the early ocean,” adds Tsukamoto. “Our findings demonstrate that hydrothermal systems could have locally supplied sufficient P to support early microbial ecosystems. These environments may have served as cradles for early life and played a significant role in the origin and evolution of life.”

    The study also highlights the potential impact of hydrothermal fields not only on the seafloor but also in terrestrial settings such as hot springs. Future research on phosphate behavior in hydrothermally altered rocks through time will further reveal shifts in P cycles on the early Earth.

    Details of the study were published in the journal Geochimica et Cosmochimica Acta on June 18, 2025.

    Phosphate behavior during submarine hydrothermal alteration of ca. 3.455 Ga basaltic seafloor rocks from Pilbara, Western Australia, Geochimica et Cosmochimica Acta

    Astrobiology

    Continue Reading